Hospital

Experts discuss current knowledge and future indications for immunotherapies and CAR T in early treatment lines.

In adolescents, a comprehensive model using behavioral and MRI data had a prediction accuracy of 0.83, which was higher than single data type models.

INCA033989 is a monoclonal antibody that selectively targets mutant calreticulin oncogenic function.

These results indicate the combination’s long-term effectiveness in a population with limited treatment options.

The discontinuation comes after a review of the medication by the European Medicines Agency which found that “the total number of deaths was higher than anticipated.”

The approval marks the only FDA-approved stand-alone therapy for the treatment of Niemann-Pick disease type C (NPC).

The study findings signal the need for improved equality in PrEP prescribing across various institutions and settings.

The decision is based on positive results from the phase 3 LAURA trial.

Artificial intelligence shows promise in improving diagnosis and treatment for patients with multiple myeloma.

Early diagnosis of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) may mitigate progression.

Long-term shedding of mutated variants could pose a concern for spread among the public.

Treatment is typically tailored to the individuals, with HCT being the only curative treatment bone marrow failure, but long-term outcomes are generally poorer due to toxicities.

Although psychotherapy is the cornerstone, nutritional education and pharmacotherapies can also help patients recover

Researchers found that PF4/Cxcl4, a key driver of fibrosis, was up regulated on all proteomes.

Compared with chemotherapy, datopotamab deruxtecan (Dato-DXd) did not achieve a statistically significant overall survival (OS) in patients with inoperable or metastatic HR+/HER2-low or negative breast cancer.

Pharmacy students discuss a non-traditional learning assignment that used the social media platform, TikTok.

William Carroll, PharmD, network vice president of pharmacy at Hackensack Meridian Health, discusses his hopes for the new partnership.

Further trials are required to examine the long-term feasibility of intravenous immunoglobulin (IVIG) for multisystem inflammatory syndrome.

Approved with 3 new indications, bimekizumab-bkzx is the first and only interleukin-17 inhibitor approved for these diseases.

Ponsegromab displayed significant and robust increases in body weight at the completion of the study for all doses.

Dermatomal reactions could occur following recombinant zoster vaccine to treat shingles.

The use of devices like Apple watches may offer a more affordable and less burdensome modality to diagnose atrial fibrillation.

Results displayed a non-inferior immune response of the co-administered vaccines, compared to administration in individual visits.

Luspatercept reduced the need for transfusion in patients with myelofibrosis (MF).

Using ultrasound and clinicopathological characteristics, the studied nomograms effectively evaluated recurrence risk in HR-/HER2+ and HR+/HER2+ breast cancer.

Patients with for HER2-positive breast cancer have an increased risk of developing brain tumors.

Though hospitalizations and test positivity remain at modest levels, wastewater analysis indicates high circulation of SARS-CoV-2, especially in western states.

The Drug Supply Chain Security Act (DSCSA) will soon mandate end-to-end tracking of pharmaceuticals throughout the supply chain, with numerous benefits for health systems.

Analyzing consolidation of 8 drug pump libraries into 1 IV infusion library in a 9-hospital system: from standardization to implementation.

The approval is based on positive results from the phase 2/3 IND.227/KEYNOTE-483 trial.